Literature DB >> 29052096

Life paths of patients with transthyretin-related familial amyloid polyneuropathy Val30Met: a descriptive study.

Alice Lopes1,2,3, Alexandra Sousa4, Isabel Fonseca4,5, Margarida Branco6,4, Carla Rodrigues4, Teresa Coelho4,7, Jorge Sequeiros8,9, Paula Freitas6,8.   

Abstract

Transthyretin-related familial amyloid polyneuropathy Val30Met is a fatal progressive disease. It is a rare hereditary amyloidosis, manifesting as a sensorimotor neuropathy and autonomic dysfunction. It begins during adulthood and is a disabling disease, posing a great psychological burden to patients and their families. Our aim was to describe and characterize life events related to the disease and discuss its psychosocial implications. Social and demographic data and a questionnaire on history of family and personal disease, and biographic events, were applied to 209 subjects attending an outpatient specialized clinic. Descriptive and statistical analyses were performed. They were 84 men and 127 women belonging to three groups: pre-symptomatic carriers, patients, and subjects with no established diagnosis. Most subjects were married/lived with a partner and had children (mean of 4). Most (96.3%) had contact with the disease before having a diagnosis; the affected or at-risk parent was the mother in 53.8% and the father in 43.3%; 71.8% of these had deceased. At their parent's death, many subjects were aged under 10 (9.9%), 10-14 (15.5%), or 15-24 years (31.7%). Most were under age 14 (44.9%) at their parent's disease onset; 37.2% referred this brought life changes with psychological and familial impact; most had been parent's caregivers; 7.5% had not been raised by the parents. Some (8.4%) declined to know their genetic tests results for over 1 year. Parent's disease and death are very common early in these patient's lives. During childhood or youth, many subjects became caregivers, implying changes in family roles. This disease and its life implications pose a significant psychosocial burden since childhood. TTR-FAP patients and their relatives are highly vulnerable to emotional stress and psychopathology during their lifetime. Psychological and psychiatric support, implying a multidisciplinary group, must thus be available for all of them.

Entities:  

Keywords:  Amyloidosis; Familial amyloid polyneuropathy; Life events; Psychiatric; Psychosocial; TTR; Transthyretin

Year:  2017        PMID: 29052096      PMCID: PMC5752657          DOI: 10.1007/s12687-017-0338-0

Source DB:  PubMed          Journal:  J Community Genet        ISSN: 1868-310X


  58 in total

Review 1.  Parental loss in childhood. Its effect in adult life.

Authors:  C Tennant
Journal:  Arch Gen Psychiatry       Date:  1988-11

2.  Parental death during childhood and psychopathology in adulthood.

Authors:  Yvonne Stikkelbroek; Peter Prinzie; Ron de Graaf; Margreet Ten Have; Pim Cuijpers
Journal:  Psychiatry Res       Date:  2012-03-15       Impact factor: 3.222

3.  Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30).

Authors:  G Holmgren; L Steen; J Ekstedt; C G Groth; B G Ericzon; S Eriksson; O Andersen; I Karlberg; G Nordén; M Nakazato
Journal:  Clin Genet       Date:  1991-09       Impact factor: 4.438

4.  Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form.

Authors:  Haruki Koike; Ken-ichiro Misu; Shu-ichi Ikeda; Yukio Ando; Masamitsu Nakazato; Eiko Ando; Masahiko Yamamoto; Naoki Hattori; Gen Sobue
Journal:  Arch Neurol       Date:  2002-11

5.  Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M).

Authors:  Diana Santos; Teresa Coelho; Miguel Alves-Ferreira; Jorge Sequeiros; Denisa Mendonça; Isabel Alonso; Carolina Lemos; Alda Sousa
Journal:  Eur J Hum Genet       Date:  2015-08-19       Impact factor: 4.246

6.  Psychological well-being and family satisfaction levels five years after being confirmed as a carrier of the Machado-Joseph disease mutation.

Authors:  Carlos Gonzalez; Elisabete Gomes; Nadiya Kazachkova; Conceição Bettencourt; Mafalda Raposo; Teresa Taylor Kay; Patrick MacLeod; João Vasconcelos; Manuela Lima
Journal:  Genet Test Mol Biomarkers       Date:  2012-12

7.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

Authors:  Teresa Coelho; David Adams; Ana Silva; Pierre Lozeron; Philip N Hawkins; Timothy Mant; Javier Perez; Joseph Chiesa; Steve Warrington; Elizabeth Tranter; Malathy Munisamy; Rick Falzone; Jamie Harrop; Jeffrey Cehelsky; Brian R Bettencourt; Mary Geissler; James S Butler; Alfica Sehgal; Rachel E Meyers; Qingmin Chen; Todd Borland; Renta M Hutabarat; Valerie A Clausen; Rene Alvarez; Kevin Fitzgerald; Christina Gamba-Vitalo; Saraswathy V Nochur; Akshay K Vaishnaw; Dinah W Y Sah; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245

8.  Childhood adversities and first onset of psychiatric disorders in a national sample of US adolescents.

Authors:  Katie A McLaughlin; Jennifer Greif Green; Michael J Gruber; Nancy A Sampson; Alan M Zaslavsky; Ronald C Kessler
Journal:  Arch Gen Psychiatry       Date:  2012-11

Review 9.  The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies.

Authors:  G Merlini; P Westermark
Journal:  J Intern Med       Date:  2004-02       Impact factor: 8.989

10.  Mid- and long-term anxiety levels associated with presymptomatic testing of Huntington's disease, Machado-Joseph disease, and familial amyloid polyneuropathy.

Authors:  Susana Lêdo; Ângela Leite; Teresa Souto; Maria A Dinis; Jorge Sequeiros
Journal:  Braz J Psychiatry       Date:  2016-02-05       Impact factor: 2.697

View more
  3 in total

1.  Phenome-wide association study of TTR and RBP4 genes in 361,194 individuals reveals novel insights in the genetics of hereditary and wildtype transthyretin amyloidoses.

Authors:  Antonella De Lillo; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Sabrina Frusconi; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  Hum Genet       Date:  2019-10-29       Impact factor: 4.132

2.  Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy.

Authors:  Lorenza Magliano; Laura Obici; Claudia Sforzini; Anna Mazzeo; Massimo Russo; Francesco Cappelli; Silvia Fenu; Marco Luigetti; Matteo Tagliapietra; Chiara Gemelli; Luca Leonardi; Stefano Tozza; Luca Guglielmo Pradotto; Giulia Citarelli; Alessandro Mauro; Fiore Manganelli; Giovanni Antonini; Marina Grandis; Gian Maria Fabrizi; Mario Sabatelli; Davide Pareyson; Federico Perfetto; Giampaolo Merlini; Giuseppe Vita
Journal:  Orphanet J Rare Dis       Date:  2021-04-07       Impact factor: 4.123

3.  Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK.

Authors:  Julian D Gillmore; Mary M Reilly; Caroline J Coats; Rob Cooper; Helen Cox; Mark R E Coyne; Andrew J Green; Ruth McGowan; William E Moody; Philip N Hawkins
Journal:  Adv Ther       Date:  2022-04-13       Impact factor: 4.070

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.